Literature DB >> 12202783

ZD1839 (Iressa) in non-small cell lung cancer.

Roy S Herbst1, Merrill S Kies.   

Abstract

Despite the advent of cisplatin-based combination chemotherapy for advanced non-small cell lung cancer (NSCLC), the prognosis for this patient population remains poor. Novel biologically targeted agents currently in development have the potential for greater efficacy against NSCLC, and possibly less toxicity than is associated with conventional cytotoxic chemotherapy. The epidermal growth factor receptor (EGFR) is recognized as a potentially useful target, and the small molecule, orally active EGFR-tyrosine kinase inhibitor ZD1839 (Iressa) is currently the furthest along in clinical development of the anti-EGFR agents. This review summarizes the currently available clinical data on the use of ZD1839 in the treatment of NSCLC.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12202783     DOI： 10.1634/theoncologist.7-suppl_4-9

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


  9 in total

Review 1.  Successful treatment of gefitinib-induced acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review.

Authors:  Li-Chiao Kuo; Po-Chou Lin; Ko-Fan Wang; Mei-Kang Yuan; Shih-Chieh Chang
Journal:  Med Oncol       Date:  2010-01-20       Impact factor: 3.064

2.  Pitfalls in immunohistochemical assessment of EGFR expression in soft tissue sarcomas.

Authors:  C Kersting; J Packeisen; B Leidinger; B Brandt; R von Wasielewski; W Winkelmann; P J van Diest; G Gosheger; H Buerger
Journal:  J Clin Pathol       Date:  2006-02-03       Impact factor: 3.411

Review 3.  Novel agents for the prevention of breast cancer: targeting transcription factors and signal transduction pathways.

Authors:  Qiang Shen; Powel H Brown
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-01       Impact factor: 2.673

4.  Comparison of gefitinib-induced skin adverse reactions (SAR) in C57BL/6 and FVB/N mice.

Authors:  Yali Zhang; Yalei Wang; Ziwei Chen; Shuo Cheng; Chengcheng Ding; Jiani Zhang; Tiantian Peng; Weihang Chen; Dingyang Zhang; Yan Tan; Xu Wang; Ruijuan Dong; Miao Jiang; Qian Hua
Journal:  Toxicol Res (Camb)       Date:  2021-03-11       Impact factor: 3.524

5.  Lessons from the ("Iressa" Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations.

Authors:  R Stahel; A Rossi; L Petruzelka; P Kosimidis; F de Braud; M M Bernardo; P-J Souquet; H Soto Parra; C Gridelli
Journal:  Br J Cancer       Date:  2003-12       Impact factor: 7.640

6.  Epidermal growth factor receptor: is it a feasible target for the treatment of osteosarcoma?

Authors:  Jun Ah Lee; Yunmi Ko; Dong Ho Kim; Jung Sub Lim; Chang-Bae Kong; Wan Hyeong Cho; Dae-Geun Jeon; Soo-Yong Lee; Jae-Soo Koh
Journal:  Cancer Res Treat       Date:  2012-09-30       Impact factor: 4.679

Review 7.  Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors.

Authors:  G Blackledge; S Averbuch
Journal:  Br J Cancer       Date:  2004-02-09       Impact factor: 7.640

8.  Tyrosine-kinase inhibition results in EGFR clustering at focal adhesions and consequent exocytosis in uPAR down-regulated cells of head and neck cancers.

Authors:  Samah Abu-Ali; Abbas Fotovati; Kanemitsu Shirasuna
Journal:  Mol Cancer       Date:  2008-06-03       Impact factor: 27.401

9.  The E3 ubiquitin ligase NEDD4 mediates cell migration signaling of EGFR in lung cancer cells.

Authors:  Genbao Shao; Ranran Wang; Aiqin Sun; Jing Wei; Ke Peng; Qian Dai; Wannian Yang; Qiong Lin
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.